A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Latest Information Update: 28 Apr 2025
At a glance
- Drugs Mobocertinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms EXCLAIM 2
- Sponsors Takeda Oncology
Most Recent Events
- 22 Apr 2025 Planned End Date changed from 30 Sep 2026 to 31 Oct 2026.
- 22 Apr 2025 Planned primary completion date changed from 30 Sep 2026 to 31 Oct 2026.
- 17 Mar 2025 Planned End Date changed from 31 Jul 2025 to 30 Sep 2026.